Alto Neuroscience Initiates Phase 2b Trial of ALTO-207 in Treatment-Resistant Depression

Alto Neuroscience, Inc., a clinical-stage biopharmaceutical company focused on precision medicines for neuropsychiatric disorders, today announced the initiation of a Phase 2b randomized, placebo-controlled trial of ALTO-207 in treatment-resistant depression (TRD), a program designed to replicate the strongly positive PAX-D study results and support a streamlined path to registration. TRD is estimated to affect up to 7 million adults in the United States, representing patients who do not respond adequately to current antidepressant therapies.